While targeted immunosuppression with CD39+ CAR Tregs could be used for auto-immune diseases like T1D, we speculate that our findings could also influence use of CD39– cytotoxic CAR Tregs in other settings, like neuroendocrine cancer targeting. This evidence concerns the gene ENTPD1 and neuroendocrine carcinoma.